Answers are grounded in this paper and cite their sources.
Surgical resection remains the primary curative-intent treatment for patients with hepatocellular carcinoma (HCC).1 However long-term outcomes remain suboptimal, with 5-year recurrence rates exceeding 60–70%,2 and recurrence remaining the leading cause of mortality.3 Given the high recurrence rates, adjuvant systemic therapy has been explored to improve outcomes. Early efforts with sorafenib failed to demonstrate benefit in the adjuvant setting.4 Immune checkpoint inhibitors (ICIs) have proven their efficacy in advanced HCC;5,6 however, these benefits have thus far not been replicated in the adjuvant setting: IMbrave050 (adjuvant atezolizumab–bevacizumab) and KEYNOTE-937 (adjuvant pembrolizumab) both failed to meet their primary endpoint to improve recurrence-free survival.
No takes yet. Share an insight, caveat, or question.
Aceituno et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: